# Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

> **NCT02447666** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 28 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Leukemia, Myelomonocytic, Juvenile

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02447666
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-15
- **Primary completion:** 2018-02-28
- **Final completion:** 2019-05-24
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02447666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02447666, "Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02447666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*